Podcasts about therapies

In this episode of The Birth Lounge Podcast, HeHe sits down with clinical pharmacist Dr. Michaela Wachal to unpack the controversy surrounding Tylenol (acetaminophen) use in pregnancy and its potential links to autism and other neurodevelopmental concerns. Together, they dive into what the research actually says (and doesn't say), why transparency and informed consent are so important, and how to navigate decisions around medications in pregnancy with confidence. Dr. Wachal also highlights the bigger picture, like how genetics, environmental toxins, and even maternal stress can play a role in outcomes, and why caring for yourself is just as critical as any prescription. This conversation is packed with nuance, evidence, and practical takeaways to help you feel informed, empowered, and ready to advocate for yourself as you make decisions about your pregnancy care. 00:00 Introduction and Media Misrepresentation 01:05 Personal Story and Birth Lounge App 02:16 Empowering Prenatal Conversations 05:26 Emergency Use Authorization Episode 07:34 Interview with Dr. Michaela Wachal 09:14 Medication Safety in Pregnancy 12:37 Pharmaceutical Industry Failures 15:20 Personal Journey and Advocacy 18:55 Questioning Medical Norms 21:15 Tylenol and Toxins 23:34 Aluminum in Vaccines 27:32 The Importance of Transparency 37:05 Advocating for Education and Understanding 37:51 The Power of Asking Questions 40:21 Nesting and Preparing for Baby 43:17 Managing Fevers During Pregnancy 52:01 Environmental Toxins and Health 01:00:41 Therapies and Support for Children on the Spectrum 01:09:27 Final Thoughts and Encouragement   Guest Bio: Michaela Wachal, PharmD, CSP, is a clinical pharmacist, Certified Specialty Pharmacist, and Clinical Accreditation Manager with nearly a decade of experience in specialty pharmacy. She holds a Doctor of Pharmacy degree from the University of Nebraska Medical Center and a Bachelor of Science in Biochemistry from Doane University. Throughout her career, she's specialized in complex conditions including oncology, fertility, endocrinology, immunology, mental health, and inflammatory diseases—always with a passion for improving patient care, optimizing healthcare systems, and empowering women in medicine. Michaela is also a mom of three, including one child with autism, ADHD, and anxiety, which ignited her deep interest in neurodiversity, integrative health, and individualized medicine. After navigating her own family's challenges, she began researching functional and evidence-based approaches to support children and families living with complex needs. Online, Michaela shares insights from scientific studies on autism, ADHD, vaccines, autoimmune conditions, toxins, and more, always with a focus on helping parents make informed, evidence-based choices. Her work blends professional expertise with personal passion, making her a trusted voice in both the pharmacy world and the parenting community.   INSTAGRAM: Connect with HeHe on IG  Connect with Dr. Wachal on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   RESEARCH MENTIONED: 2021 there's a call for action published supported by 91 scientists, clinicians and public health professionals across the globe recommended that pregnant women should be cautioned at the beginning of pregnancy to forego APAP unless it is medically indicated and to minimize the exposure by using the lowest effective dose for shortest possible time https://pubmed.ncbi.nlm.nih.gov/34556849/   Boston Birth cohort published in 2020 looked at acetaminophen metabolites in cord blood samples collected at birth and unchanged acetaminophen levels were detected in all cord plasma samples and acetaminophen burden was associated with higher odds of ADHD  and ASD daignosis there was a 2.3 to 3.5 increased risk for ADHD and 1.6 to 4.1 increased risk for ASD https://pubmed.ncbi.nlm.nih.gov/31664451/   Recently in August Harvard did an analysis using the Navigation Guide methodology that supports evidence consistent with an association between acetaminophen exposure during pregnancy and increased incidence of Neurodevelopmental disorders. This included 46 studies with 27 reporting positive associations with the higher quality studies more likely to show positive correlations https://ehjournal.biomedcentral.com/articles/10.1186/s12940-025-01208-0   Nurses Health Study https://pubmed.ncbi.nlm.nih.gov/30923825/ Spanish birth cohort where acetaminophen exposure was associated with more hyperactivity/impulsivity https://pubmed.ncbi.nlm.nih.gov/27353198/   In 2018 there was a review that showed that 9 prospective cohort studies that all suggested an association between prenatal APAP exposure and neurodevelopmental outcomes - ADHD, ASD or lower IQ and longer duration was associated with increased risk https://pubmed.ncbi.nlm.nih.gov/29341895/   2022 a prospective cohort study in Pennsylvania looked at 2,423 moms using data and children who were exposed to APAP during pregnancy scored higher for child behaviors, sleep problems and attention problems  https://pubmed.ncbi.nlm.nih.gov/36170224/ Keywords: Tylenol pregnancy, acetaminophen pregnancy, Tylenol autism risk, pregnancy medication safety, prenatal care, evidence-based pregnancy, maternal health, neurodevelopment, pregnancy decision making, informed consent pregnancy, pregnancy medications, Dr. Michaela Wachal, Birth Lounge podcast, pregnancy self-care, pregnancy toxins

In this episode of the Xtalks Life Science Podcast, Senior Life Science Journalist Ayesha Rashid speaks with Joel Latham, CEO, president and director of Incannex Healthcare, to discuss how the company is advancing cannabinoid and psychedelic therapies for chronic conditions like sleep apnea, rheumatoid arthritis and anxiety disorders. Joel has more than 20 years of senior management and operations experience in both public and private sectors. Under Joel's leadership, Incannex has advanced and prioritized multiple therapeutic candidates into clinical-stage development. Previously, he was the CEO and Managing Director of Incannex Australia, where he played a key role in the company's growth and its successful transition to Nasdaq. Joel has also held senior leadership roles in corporate strategy and global market development at Mars Foods, Tabcorp and Philip Morris International. Listen now to learn about the cutting-edge developments in cannabinoid and psychedelic medicine. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Moderator: Amit Bobby Mahajan, MD, FCCP, DAABIP Guest: Jonathan Kurman, MD Guest: Surya Bhatt, MD New strategies like advanced pharmacologic agents and bronchoscopic lung volume reduction are redefining COPD and emphysema management. Dr. Bobby Mahajan sits down with Drs. Surya Bhatt and Jonathan Kurman to highlight emerging strategies for identifying ideal candidates, optimizing patient selection, and combining therapies to reduce dyspnea and improve outcomes. Dr. Mahajan is the Medical Director of Interventional Pulmonology and Complex Airway Disease Programs at the Inova Health System in Virginia, Dr. Bhatt is the Director of the Center for Lung Analytics and Imaging Research as well as the Medical Director of the Pulmonary Function and Exercise Physiology Lab and the Pulmonary Rehabilitation Program at the University of Alabama at Birmingham, and Dr. Kurman is an Associate Professor of Medicine at the Medical College of Wisconsin and the Director of Interventional Pulmonology at Froedtert and Medical College of Wisconsin Health Network. This program is produced in partnership with the American College of Chest Physicians and is sponsored by Pulmonx, the maker of the Zephyr Valve.

Drs. Hindiyeh and Hutchinson review new FDA-issued safety warnings for Raynaud's phenomenon and hypertension in CGRP-based migraine treatment. They explore the impact of this label update and share practical strategies for patient management.

In this episode of SurgOnc Today, SSO Peritoneal Surface Malignancy Disease Site Working Group members Dr. Alissa Greenbaum and Dr. Omar Llaguna moderate a discussion with Dr. Maheswari Senthil of UC Irvine and Dr. Richard Alexander of the Rutgers Cancer Institute of New Jersey to dive deep into the history of the development of regional therapies such as HIPEC and PIPAC in the United States. The expert discussants answer tough questions regarding the ethical considerations of modern clinical trials and the implementation of experimental therapies into practice.

Simplify pediatric eczema regimens with once-daily, nonsteroidal treatments. See what's making a difference for young patients and families. Credit available for this activity expires: 9/25/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/framing-future-topical-therapies-atopic-dermatitis-2025a1000p2a?ecd=bdc_podcast_libsyn_mscpedu

Nicotine for memory? Methylene blue for mitochondria? Dr. Josh Axe breaks down 10 controversial compounds—what the science says, what's overhyped, and the key safety and legality questions to ask before you even think about trying them. Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: https://www.youtube.com/@drjoshaxe?sub_confirmation=1 

Our bodies are naturally designed to heal. But interruptions in energy flow or “blockages” can lead to pain, inflammation, and reduced vitality. Brendan Legel, COO of First Alternative Therapies, helps clients live pain-free without drugs. They use advanced tools like Avazzia microcurrent biofeedback, PEMF (Pulsed Electromagnetic Field) therapy, and molecular hydrogen treatments. These therapies communicate […]

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Dallas/Fort Worth–based dermatologist Todd Plott, MD, for an in-depth discussion on the first extended-release formulation of minocycline approved for rosacea. The conversation begins with a historical look at tetracyclines, tracing back to tetracycline in 1953, doxycycline in 1968, and minocycline in 1971. While traditionally used as broad-spectrum antibiotics, these agents have shown efficacy in rosacea primarily due to their anti-inflammatory activity rather than antimicrobial effects. They review head-to-head clinical data showing that extended-release minocycline, commercially available as Emrosi, significantly reduced inflammatory lesions and improved Investigator Global Assessment scores in patients with moderate-to-severe rosacea, outperforming both modified-release doxycycline and placebo. The trial population averaged 25 papules per patient, demonstrating the robust improvement required for trial success. A key point of discussion is minocycline's narrow therapeutic window. While higher doses have raised concerns about adverse effects such as hyperpigmentation and lupus-like drug reactions, pharmacokinetic data show that extended-release dosing achieves lower systemic exposure with fewer safety issues compared to immediate-release formulations. Dr Plott contextualizes this by noting that dermatology indications require far lower doses than in infectious disease, which helps explain the rationale for the extended-release formulation in rosacea. Tune in to the full episode to learn more about how extended-release minocycline and anti-inflammatory dosing fit into current rosacea treatment options, what the latest evidence shows about its efficacy and safety, and how clinicians can gain refreshed perspectives on this long-standing therapy.

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.

Why You Should Listen:  In this episode, you will learn about breakthrough therapies for chronic illness recovery including EBOO and TPE. About My Guest: My guest for this episode is Dr. Tami Lyday.  Tami Lyday, DO, MS has been a physician since 2006 and a functional and integrative specialist since 2017.  Prior to that, she spent 11 years as a family practitioner but was never quite satisfied with conventional medical approaches.  Her mother's illness and subsequent side effects of traditional treatments prompted her to learn more about integrative medicine, and she has not looked back.  Dr. Lyday believes functional and integrative medicine is the best way to ensure lasting recovery as it helps patients determine the root of their health issues and does not rely on medications that treat symptoms while ignoring the underlying causes of illness.  She pursued training and certifications in functional and integrative medicine, including specialty training and certifications in the treatment of mold-related illnesses and Lyme disease. At the time of her certification, she was one of only 26 practitioners in the world who were Shoemaker certified in mold treatment protocols.  After 4 years as a functional and integrative medical practitioner, she opened The Lyday Center to provide a dedicated resource for people who are suffering from mystery illnesses and ailments that don't respond to conventional treatment and are seeking natural solutions to their chronic illnesses.  Since that time, she has expanded her specialties to include the treatment of thyroid disorders and overall energy levels.  Her mission is to heal the world one patient at a time. Key Takeaways: How much does environmental toxicity contribute to chronic illness? How is a patient tested for mold illness? What binders are most commonly used for detoxification?  Do natural binders have a place? What is the role of Actinobacteria and endotoxins in CIRS patients? Can a patient have fungal colonization and potentially benefit from antifungals? Does treating mold also treat Lyme and coinfections? How important is working on the limbic system to set the stage for healing? How might EBOO and TPE support those with autoimmunity? Where in a recovery timeline do EBOO and TPE best fit? Does Hashimoto's occur without mold? What is the role of EBOO?  What is the EBOO process? What is done before and after EBOO to support the patient? Can patients have detoxification or Herxheimer reactions after EBOO or TPE? How might EBOO and TPE help those with Long COVID? What types of infections might EBOO support? What is the role of TPE?  What is the TPE process? What types of toxicants and toxins can be filtered out? How is the removed plasma replaced Might beneficial materials be removed with TPE? Can EBOO or TPE help those with neurodegenerative conditions? Connect With My Guest:  TheLydayCenter.com Interview Date: September 5, 2025 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode222. Additional Information: To learn more, visit https://BetterHealthGuy.com. Follow Me on Social Media: Facebook - https://facebook.com/betterhealthguy Instagram - https://instagram.com/betterhealthguy X - https://twitter.com/betterhealthguy TikTok - https://tiktok.com/@betterhealthguy Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

In this AANEM session, Chilvana Patel, MD moderates a discussion with Pushpa Narayanswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD on the evolving treatment landscape in myasthenia gravis (MG). The panel reviews the use of targeted therapies in women of childbearing age with myasthenia gravis, alongside guidance for perioperative care before elective surgery. Through illustrative patient cases, the experts provide insight into practical challenges and emerging opportunities in tailoring advanced immunotherapies to individual patient needs.

This is the best! A great conversation with Katie Asmus!Katie Asmus is a Somatic and Nature-Based Psychotherapist. With a Master's degree in Somatic Psychology, over 30 years of leading individuals and group programs out in nature, and a lifetime of apprenticing to ceremony and rites of passage, Katie says the essence of her work is normalizing, celebrating, and bringing compassion to what it means to be human.  For the past 20 years, alongside maintaining a private psychotherapy practice, she has taught graduate students at Naropa University and Prescott College in the areas of Somatic and Nature-based Therapies. In addition, through the Somatic Wilderness Therapy Institute (and in collaboration with other inspiring colleagues), she created and facilitates both online and in-person workshops and trainings in Somatic Trauma work, Ceremony & Rites of Passage facilitation, as well as in a wide variety of wilderness, adventure, and nature-based therapy skills. Having sat with thousands of people from around the world and from all walks of life, Katie is a tender of the thresholds and strongly believes in the necessity of following our deepest longing while simultaneously knowing and feeling our interconnection and belonging to the greater web of life.Relevant LinksSomatic Nature Therapy InstituteMore About KatiePsychology TodayLinkedInKatie on Will White's Stories from the FieldKatie on The Awakened TherapistKatie on Therapy in the Great OutdoorsMore Ways to ConnectSocial Sciences Week Outdoor Therapy Series 2025

Send us an email @ info@parentcoachesunleashed.com SummaryIn this episode of Parent Coaches Unleashed, hosts Jessica Anger and Carrie Wiesenfeld welcome Jane Kaufman, a mother of two young adults, one of whom is neurodivergent. The conversation explores Jane's journey navigating the complexities of raising a child with autism, the importance of community support, and the challenges of finding appropriate therapies and resources. Jane shares personal anecdotes, insights on family dynamics, and advice for parents facing similar challenges. The discussion emphasizes the significance of self-care, humor, and trusting one's instincts in the parenting journey.TakeawaysThe importance of community support for parents of neurodivergent children.Therapies and early intervention can significantly impact a child's development.Family dynamics play a crucial role in supporting neurodivergent individuals.Navigating medical professionals can be challenging; trust your instincts.Self-care is essential for parents managing overwhelming situations.It's okay to feel overwhelmed and seek help from others.Building independence in neurodivergent children is a gradual process.Sibling relationships can be complex but are vital for emotional support.Using humor can help cope with the challenges of parenting.Every child's journey is unique; avoid comparisons with others.titles

With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by significant barriers that discourage widespread adoption. In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker speaks with Glenn Pierce, M.D., Ph.D., vice president of medical at the World Federation of Hemophilia, about the complexities behind these innovative therapies and the multifaceted reasons for their slow uptake. Pierce discusses the competitiveness of the current hemophilia gene therapy market, why Pfizer’s product couldn’t keep up, and the patient populations that risk being left behind. To learn more about the topics in this episode: As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio BioMarin downsizes Roctavian efforts but keeps hemophilia gene therapy for 3 markets See omnystudio.com/listener for privacy information.

What you need to know to help patients and families decide about amyloid-targeting therapies for early-stage Alzheimer's disease. Credit available for this activity expires: 9/8/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002882?ecd=bdc_podcast_libsyn_mscpedu

We love to hear from our listeners. Send us a message.On episode 111 of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). Luther shares how Ernexa's synthetic, standardized, off-the-shelf iMSCs are designed to overcome historic hurdles in MSC therapy, including variability, scalability, and manufacturing complexity, by leveraging master cell banks, precise gene editing, and novel product engineering. He also shares insights into the process of developing pro- and anti-inflammatory iMSCs for oncology and autoimmunity.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Are you up to date with therapy strategies for ALK translocation and EGFR mutation–positive non-small cell lung cancer? Credit available for this activity expires: 9/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002896?ecd=bdc_podcast_libsyn_mscpedu

Join us for an in-depth conversation with Dr. Aahd Kubbara, a practicing pulmonologist, intensivist, and Assistant Professor of Medicine at the University of Minnesota Medical Center. Dr. Kubbara specializes in pulmonary, allergy, critical care, and sleep medicine, with advanced expertise in interstitial lung disease, asthma, and targeted biological therapies. In this episode, we explore the complexities of lung health and the latest strategies for preventing and managing chronic respiratory conditions: ·       How inflammatory lung diseases can cause long-term scarring. ·       The consequences of untreated or poorly managed asthma over time. ·       What pulmonary fibrosis is and the most effective approaches to treatment. ·       The risks of normalizing chronic respiratory symptoms. ·       Seasonal asthma triggers and how to reduce their impact. With years of experience at the Mayo Clinic and University of Nevada, as well as community pulmonary care practice, Dr. Kubbara offers insights into cutting-edge therapies, personalized medicine, and preventive strategies to maintain lung health. Learn more about Dr. Kubbara and his work in pulmonary medicine here! Episode also available on Apple Podcasts: https://apple.co/38oMlMr  Keep up with Dr. Aahd Kubbara socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en  X : https://x.com/aahdkubbara 

Dr. Tony Ebel addresses one of the most common challenges facing families with chronically ill children: healing interventions overload. Many parents are managing multiple therapies, dozens of supplements, and restrictive diets while feeling like nothing works and their child remains stuck or regresses.Dr. Tony reveals the counterintuitive truth that the most advanced healing approach is "less is more." He explains how well-intentioned interventions can overwhelm a child's already stressed nervous system. The solution is a three-phase approach: Phase 1 focuses exclusively on foundational Neurologically-Focused Chiropractic Care, Phase 2 gradually reintroduces therapies, and Phase 3 is where breakthrough healing occurs. The key message: healing comes from proper sequencing and the child's innate ability, not from piling on more interventions.Key Topics & Timestamps([00:00:00]) - The Overload Crisis - How millions of parents are overwhelmed managing multiple interventions without seeing results([00:04:00]) - When Good Interventions Go Bad - Why overwhelmed nervous systems cause children to plateau or regress despite "doing everything right"([00:09:00]) - Less Is More Philosophy - The advanced approach prioritizes foundation and sequencing over doing everything at once([00:11:00]) - The Computer & Circuit Breaker Analogies - Relatable explanations of how nervous system overload works([00:15:00]) - The Energy Theft Hierarchy - Scientific breakdown of how stress systematically affects gut, immune, and motor systems([00:21:00]) - The Three-Phase Action Plan - Foundation first (Phase 1), gradual reintroduction (Phase 2), breakthrough healing (Phase 3)([00:28:00]) - The Patience Factor & Next Steps - Honest discussion about the difficulty of slowing down and practical guidance for getting started-- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click HereSubscribe, share, and stay tuned for more incredible episodes unpacking the power of Nervous System focused care for children!

As anti-inflammatory rescue therapies begin making their way to patients with asthma, new questions about implementation of this life-saving therapy are emerging, prompting more exciting research from scientists and clinicians. In the first part of this mini-series on anti-inflammatory rescue therapies, host Amy Attaway, MD, of Cleveland Clinic, discusses these questions and more with asthma expert Njira Lugogo, MD, of University of Michigan. This episode of the ATS Breathe Easy podcast is supported in part by AstraZeneca. 

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

Today on The One Life Radio Podcast, Jennifer Dillon and Bernadette Fiaschetti discuss Jennifer's book “A New Era of Healing - A Comprehensive Guide To Innovative Therapies.” If you like real and relatable this podcast is for you! Bern and Jenny let their long hair all the way down! Jennifer Dillon is an integrated nutrition specialist who founded OhZone Clinics, specializing in dietary theories and lifestyle coaching. Her commitment to cutting-edge therapeutic approaches was galvanized by her son's recovery from frequent illnesses and neurological issues that persisted for over two years.Encountering Ozone Therapy as a last resort, Dillon witnessed her son's health transformation, prompting her dedication to helping others navigate similar health crises.Today Jennifer Dillon attracts clients worldwide, driven by her desire to educate on natural healing and proactive health maintenance in toxin filled world.You can find and learn more about Jennifer Dillon at her website https://www.ohzoneclinics.com/

Send us a textIn this Tech Tuesday episode, Ben speaks with Laurence Gulliver, General Manager for Humidification at Fisher & Paykel Healthcare. With nearly two decades at the company and a background in mechanical engineering and product development, Laurence has helped guide innovations that have shaped respiratory support for neonatal, pediatric, and adult patients worldwide.The conversation explores the role of humidification in neonatal respiratory care and why it is often overlooked despite its impact on mucociliary function, secretion management, bronchoconstriction, and thermoregulation. Laurence explains the engineering challenges of delivering consistent humidity through ventilator circuits, the burden of condensation management, and how newer platforms like the F&P 950 are designed to improve performance and usability.They also discuss Fisher & Paykel's approach to product development, which relies heavily on feedback from caregivers to ensure technology addresses real-world challenges. The episode closes with a broader look at CPAP therapy, opportunities for further innovation in a seemingly simple modality, and the global vision that drives Fisher & Paykel to design solutions adaptable to diverse healthcare settings.This conversation highlights how thoughtful engineering and collaboration with caregivers translate into meaningful improvements in neonatal outcomes.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases. Cardiol's lead asset, CardiolRx™, is currently in: A Phase 3 trial (Maverick Study) for recurrent pericarditis, enrolling patients at world-leading centers including the Cleveland Clinic, Mayo Clinic, and Mass General. A Phase 2 trial (ARCHER Study) for acute myocarditis, where recently released top-line results showed promising impacts on heart size and function. We also cover: The company's orphan drug designation from the FDA and its implications for market exclusivity. Development of CRD-38, a next-generation therapy designed for heart failure - a market with multi-billion-dollar potential. Cardiol's capital position, with funding secured well into 2026. Key upcoming milestones for investors, including full data presentations, trial updates, and potential pharma partnerships.   Please email me any further questions you have for David. My email address is Fleck@kereport.com.  Click here to learn more about Cardiol Therapeutics.

Send us a textIn this episode of The Incubator Podcast, Dr. Guilherme Sant'Anna, Professor of Pediatrics at McGill University, joins Ben and Daphna to discuss his team's work on implementing an early bubble CPAP protocol in the delivery room. Although CPAP has long been considered standard practice for preterm infants, Dr. Sant'Anna explains why intubation rates remain high in the most immature babies and how his group sought to change this pattern.The conversation reviews the background of the protocol, which began at McGill in 2014, and the cultural shift required to adopt bubble CPAP as the default approach. Dr. Sant'Anna describes the importance of multidisciplinary training, technical details such as proper prong sizing, fixation, humidification, and suctioning, as well as the challenges of sustaining practice change over a decade.The results of this initiative are striking: lower rates of delivery room intubation, reduced severe BPD, and improvements in outcomes particularly for infants born before 28 weeks. Dr. Sant'Anna also reflects on lessons learned, the global implications of bubble CPAP in resource-limited settings, and the importance of sharing knowledge to improve care everywhere.This episode highlights how attention to detail, persistence, and team culture can transform neonatal respiratory care.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Immunotherapies hold enormous promise for treating cancers of various types, but the bad news is that while many patients may initially respond many will also become resistant. Valsamo Anagnostou, a cancer researcher at Johns Hopkins, is looking at tumor specific … Assessing individual cancer characteristics is needed to determine resistance to new types of therapies, Elizabeth Tracey reports Read More »

Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Are "anti-aging" interventions misleadingly oversimplified, and what does the science actually say about their impact on real longevity? In this episode of the Vibrant Wellness podcast, host Dr. Emmie Brown is joined by Dr. Kyle Gillett, founder of Gillett Health and a leader in holistic, evidence-based longevity medicine. Dr. Gillett brings his expertise in hormone and peptide therapies, preventive medicine, sports medicine, and genomics to the table, offering a masterclass in designing individualized health plans for anti-aging, or more precisely, healthy longevity.The conversation takes a deep dive into the nuances and common misconceptions around hormone therapy, particularly the debate over bioidentical versus synthetic hormones and the importance of context in interpreting society guidelines. Dr. Gillett is candid about the pitfalls of oversimplifying anti-aging interventions and highlights the sophistication needed to personalize care, especially when using hormone replacement or peptide protocols. For practitioners seeking to elevate their approach to longevity medicine, this episode is a treasure trove of actionable wisdom.Key Takeaways from Today's Episode:

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Using biomarker testing and APOE genotyping to determine patient eligibility for amyloid-targeting therapies. Credit available for this activity expires: 8/19/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002844?ecd=bdc_podcast_libsyn_mscpedu

Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite literally bone cancer. It happens in teenagers like Olivia, after the growth comes together in the long bones, and there's some sort of miscalculation, and a very aggressive and very deadly cancer develops from that of the growth. And as a result, the cancer can usually spread to the lungs and then the brain. And that's where it gets very, very deadly. And our approach is to stimulate the immune system with a weakened or attenuated listeria that fires up the immune system and goes and finds these little culprits, little micro metastases that have survived the chemo and radiation that these kids go through. It tries to destroy those little micro metastases before they land in the lungs and the brain." Olivia elaborates, "I talk to patients all the time. Actually, I was introduced to people who became close friends during my actual treatment, but today I still do physical therapy and I'm constantly meeting kids who are in the middle of treatment and some of them have relapse, some haven't, but so I'm constantly meeting new patients and it's just evident that we need better treatment options. I see how weak they are from chemo. They're all, especially with osteosarcoma, you usually have to have a joint replacement or amputation, and chemo just weakens you. So it makes it even harder to recover from that. And I mean, these treatments are just so old. And so for sure, seeing all of these patients going through active treatment just reinforces how badly we need new treatment options, especially treatment options like surgery and immunotherapy." #OSTherapies #Osteosarcoma #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #ComparativeOncology #CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite literally bone cancer. It happens in teenagers like Olivia, after the growth comes together in the long bones, and there's some sort of miscalculation, and a very aggressive and very deadly cancer develops from that of the growth. And as a result, the cancer can usually spread to the lungs and then the brain. And that's where it gets very, very deadly. And our approach is to stimulate the immune system with a weakened or attenuated listeria that fires up the immune system and goes and finds these little culprits, little micro metastases that have survived the chemo and radiation that these kids go through. It tries to destroy those little micro metastases before they land in the lungs and the brain." Olivia elaborates, "I talk to patients all the time. Actually, I was introduced to people who became close friends during my actual treatment, but today I still do physical therapy and I'm constantly meeting kids who are in the middle of treatment and some of them have relapse, some haven't, but so I'm constantly meeting new patients and it's just evident that we need better treatment options. I see how weak they are from chemo. They're all, especially with osteosarcoma, you usually have to have a joint replacement or amputation, and chemo just weakens you. So it makes it even harder to recover from that. And I mean, these treatments are just so old. And so for sure, seeing all of these patients going through active treatment just reinforces how badly we need new treatment options, especially treatment options like surgery and immunotherapy." #OSTherapies #Osteosarcoma #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #ComparativeOncology #CanineOsteosarcoma ostherapies.com Download the transcript here

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Breakthroughs in cancer research are playing a pivotal role in advancing treatments and therapies to fight the disease. Discover Advancements in Cancer Research, Treatments, and Therapies, inside this edition of CTSI Discovery Radio!

19keys.com/tour to get your tickets today19keys.com/links or 19keystour@togmail.com to Support for the tour (venue partners, sponsors, team, etc) 19keys.com/links to sign of for Yah'ki Awakened x 19Keys Retreat Experience

In today's episode, we connect with Dr. Aahd Kubbara to discuss the intricacies of lung function and targeted biological therapies for asthma. Dr. Kubbara is a practicing pulmonologist and intensivist at the University of Minnesota Medical Center, where he also serves as an Assistant Professor of Medicine, Pulmonary, Allergy, Critical Care, and Sleep and Associate Program Director of the Pulmonary and Critical Care Fellowship. Hit play to discover: The types of inflammatory diseases that can lead to lung scarring. The consequences of untreated asthma over years of time. What pulmonary fibrosis is, and how to treat it. The potential impacts of normalizing chronic health symptoms. How seasonal asthma is typically triggered and how to mitigate it. Dr. Kubbara brings a wealth of experience to his field, including a year in Critical Care at the Mayo Clinic in Rochester, and another year in Academic Pulmonary and Critical Care at the University of Nevada, Reno. He also spent a year practicing community Pulmonary and Critical Care at both Mayo Clinic Eau Claire and Aspirus Wausau Hospital. In addition, he completed an advanced fellowship in Interstitial Lung Disease and Vasculitis at the Mayo Clinic. To learn more about Dr. Kubbara and his work, click here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C Keep up with Julian R. Gershon Jr. socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en  X : https://x.com/aahdkubbara 

In this Huberman Lab Essentials episode, I discuss both healthy eating and clinically recognized eating disorders, including anorexia, bulimia and binge eating disorder. I explain how brain circuits, hormones such as leptin and reward systems interact to regulate appetite, satiety and overall eating behaviors. I also discuss the serious health risks associated with anorexia, explain how disrupted eating habits contribute to its development and highlight evidence-based treatments for anorexia. Finally, I explore binge eating and bulimia, discussing the underlying causes and the pharmacological treatments commonly used to support recovery. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Eating Disorders 00:01:05 Fasting, Intermittent Fasting, Healthy Eating 00:06:10 Self-Diagnosis Caution 00:07:20 Sponsor: LMNT 00:08:52 Eating Disorders, Anorexia Nervosa 00:12:39 Hunger & Satiety; Appetite, Body Fat & Brain 00:17:20 Homeostasis & Reward Systems, Eating Disorders 00:21:12 Sponsor: AG1 00:22:49 Anorexia, Puberty, Hyperacuity & Food 00:25:55 Decision-Making vs Reflexes/Habits, Anorexia 00:29:29 Anorexia & Breaking Habits, Therapies & Family-Based Models 00:32:08 Distorted Self-Image & Anorexia 00:35:03 Sponsor: Function 00:36:43 Bulimia & Binge-Eating Disorder, Impulsivity & Prescription Treatments 00:40:28 Recap & Key Takeaways Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices